MG 56

Drug Profile

MG 56

Alternative Names: MG56-I; MG56-II; MG56-III; MG56-IV; MG56-V; MG56-VI; MG56-VII; MG56-VIII; Pollen allergen extracts - Inmunotek

Latest Information Update: 31 Dec 2015

Price : $50

At a glance

  • Originator Inmunotek
  • Class Allergens; Allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Allergic rhinitis; Allergic rhinoconjunctivitis

Most Recent Events

  • 27 Nov 2015 Phase-II clinical trials in Allergic rhinitis and Allergic rhinoconjunctivitis in Spain (SC and Sublingual) (EudraCT2014-005471-88)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top